Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury

Hypertension

Volumn 67, Issue 1, 2016, Pages 99-106

  Ayuzawa, Nobuhiro ^a   Nagase, Miki ^c   Ueda, Kohei ^a   Nishimoto, Mitsuhiro ^a   Kawarazaki, Wakako ^a   Marumo, Takeshi ^a,d   Aiba, Atsu ^b   Sakurai, Takayuki ^e   Shindo, Takayuki ^e   Fujita, Toshiro ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

aldosterone; heart failure; hypertension; NADPH oxidase; Rac1

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ATRIAL NATRIURETIC FACTOR; EPLERENONE; MINERALOCORTICOID RECEPTOR; MYOSIN HEAVY CHAIN BETA; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; MINERALOCORTICOID ANTAGONIST; NEUROPEPTIDE; RAC1 PROTEIN, MOUSE; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CARDIAC DYSFUNCTION; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; HEART DISEASE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HETEROZYGOTE; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; PRESSURE OVERLOAD INDUCED CARDIAC INJURY; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; DISEASE MODEL; DRUG EFFECTS; HEART FAILURE; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCYTES, CARDIAC; NEUROPEPTIDES; OXIDATIVE STRESS; RAC1 GTP-BINDING PROTEIN; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 84951568074     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06054     Document Type: Article

References (48)

1. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761. doi: 10.1161/CIRCULATIONAHA.106.653964.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. doi: 10.1056/NEJM199909023411001.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. doi: 10.1056/NEJMoa030207.
4. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi: 10.1056/NEJMoa1009492.
5. López-Andrés N, Iñigo C, Gallego I, Díez J, Fortuño MA. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology. 2008;149:4970-4978. doi: 10.1210/en.2008-0120.
6. Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, Reichelt ME, Delbridge LM, Young MJ. Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension. 2012;60:1443-1450. doi: 10.1161/HYPERTENSIONAHA.112.203158.
7. Le Menuet D, Munier M, Meduri G, Viengchareun S, Lombès M. Mineralocorticoid receptor overexpression in embryonic stem cellderived cardiomyocytes increases their beating frequency. Cardiovasc Res. 2010;87:467-475. doi: 10.1093/cvr/cvq087.
8. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033. doi: 10.1161/CIRCULATIONAHA.104.503706.
9. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400-408. doi: 10.1161/CIRCULATIONAHA.110.983023.
10. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, Barreto F, Bauersachs J, Schütz G, Hein L. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011;57:746-754. doi: 10.1161/HYPERTENSIONAHA.110.163287.
11. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664. doi: 10.1161/01. HYP.0000203772.78696.67.
12. Massaad C, Houard N, Lombès M, Barouki R. Modulation of human mineralocorticoid receptor function by protein kinase A. Mol Endocrinol. 1999;13:57-65. doi: 10.1210/mend.13.1.0226.
13. Funder JW. Is aldosterone bad for the heart? Trends Endocrinol Metab. 2004;15:139-142. doi: 10.1016/j.tem.2004.03.006.
14. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010;55:813-818. doi: 10.1161/HYPERTENSIONAHA.109.149062.
15. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370-1376. doi: 10.1038/nm.1879.
16. Shibata S, Mu S, Kawarazaki H, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptordependent pathway. J Clin Invest. 2011;121:3233-3243. doi: 10.1172/JCI43124.
17. Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, Ueda K, Fujita T. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol. 2012;23:997-1007. doi: 10.1681/ASN.2011070734.
18. Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S, Fujita T. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension. 2012;59:500-506. doi: 10.1161/HYPERTENSIONAHA.111.185520.
19. Higashikuni Y, Sainz J, Nakamura K, Takaoka M, Enomoto S, Iwata H, Tanaka K, Sahara M, Hirata Y, Nagai R, Sata M. The ATP-binding cassette transporter ABCG2 protects against pressure overload-induced cardiac hypertrophy and heart failure by promoting angiogenesis and antioxidant response. Arterioscler Thromb Vasc Biol. 2012;32:654-661. doi: 10.1161/ATVBAHA.111.240341.
20. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101:7618-7623. doi: 10.1073/pnas.0307512101.
21. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol. 2006;406:554-565. doi: 10.1016/S0076-6879(06)06043-5.
22. Kassai H, Terashima T, Fukaya M, Nakao K, Sakahara M, Watanabe M, Aiba A. Rac1 in cortical projection neurons is selectively required for midline crossing of commissural axonal formation. Eur J Neurosci. 2008;28:257-267. doi: 10.1111/j.1460-9568.2008.06343.x.
23. Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, Behringer RR, Schneider MD. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc Natl Acad Sci U S A. 2002;99:2878-2883. doi: 10.1073/pnas.042390499.
24. Sano M, Izumi Y, Helenius K, et al. Ménage-à-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1. Cell Metab. 2007;5:129-142. doi: 10.1016/j.cmet.2007.01.003.
25. Hernández-Díaz I, Giraldez T, Arnau MR, Smits VA, Jaisser F, Farman N, Alvarez de la Rosa D. The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology. 2010;151:3888-3899. doi: 10.1210/en.2010-0099.
26. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006;103:7432-7437. doi: 10.1073/pnas.0510444103.
27. Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q, Arnold JM, Peng T. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes. 2009;58:2386-2395. doi: 10.2337/db08-0617.
28. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427. doi: 10.1161/01.CIR.0000153800.09920.40.
29. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010;106:1253-1264. doi: 10.1161/CIRCRESAHA.109.213116.
30. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296.
31. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010;107:15565-15570. doi: 10.1073/pnas.1002178107.
32. Matsushima S, Kuroda J, Ago T, Zhai P, Park JY, Xie LH, Tian B, Sadoshima J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res. 2013;112:651-663. doi: 10.1161/CIRCRESAHA.112.279760.
33. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res. 2003;93:802-805. doi: 10.1161/01. RES.0000099504.30207.F5.
34. Sheppard KE, Autelitano DJ. 11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology. 2002;143:198-204. doi: 10.1210/endo.143.1.8583.
35. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008;133:340-353. doi: 10.1016/j.cell.2008.01.052.
36. Fejes-Tóth G, Náray-Fejes-Tóth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology. 2007;148:1502-1510. doi: 10.1210/en.2006-1438.
37. Latouche C, Sainte-Marie Y, Steenman M, Castro Chaves P, Naray-Fejes-Toth A, Fejes-Toth G, Farman N, Jaisser F. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology. 2010;151:4467-4476. doi: 10.1210/en.2010-0237.
38. Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature. 1991;353:668-670. doi: 10.1038/353668a0.
39. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal. 2006;18:69-82. doi: 10.1016/j. cellsig.2005.03.023.
40. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Fórró L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007;406:105-114. doi: 10.1042/BJ20061903.
41. Michea L, Villagrán A, Urzúa A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension. 2008;52:295-300. doi: 10.1161/HYPERTENSIONAHA.107.109645.
42. Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, Sun XN, Yang QZ, Ma SM, Huang B, Berger S, Wang W, Wu Y, Yu Y, Duan SZ, Mortensen RM. Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One. 2014;9:e110950. doi: 10.1371/journal.pone.0110950.
43. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120:3350-3364. doi: 10.1172/JCI41080.
44. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-543. doi: 10.1161/HYPERTENSIONAHA.109.131110.
45. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008;102:1359-1367. doi: 10.1161/CIRCRESAHA.108.174235.
46. Gravez B, Tarjus A, Pelloux V, Ouvrard-Pascaud A, Delcayre C, Samuel J, Clément K, Farman N, Jaisser F, Messaoudi S. Aldosterone promotes cardiac endothelial cell proliferation in vivo. J Am Heart Assoc. 2015;4:e001266. doi: 10.1161/JAHA.114.001266.
47. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension. 2014;63:1033-1040. doi: 10.1161/HYPERTENSIONAHA.113.01803.
48. Liu WF, Nelson CM, Tan JL, Chen CS. Cadherins, RhoA, and Rac1 are differentially required for stretch-mediated proliferation in endothelial versus smooth muscle cells. Circ Res. 2007;101:e44-e52. doi: 10.1161/CIRCRESAHA.107.158329.